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Abstract 
The A.P.P.A.® Project [1] is the result of the cooperation between the Pharmacy Faculty (TO) and local Pharmacists and it is in agreement with the International Health Cooperation principles. The 
Project is structured in six phases, through which it is possible to obtain an effective and functional galenic lab in hospitals located in developing Countries (DC). Due to the different socio-economic 
conditions each lab is a reality different from the others, always without forgetting the goal of opening labs that produce quality medicinal products. For each lab a specific handbook has been studied: 
each of them reflects the different local needs. For this reason, in the last two labs carried out in Angola and Haiti, it was necessary to introduce several formulations for pediatric use. For each 
preparation specific tests were performed to verify the stability under different environmental conditions, in accordance with the European Medicines Agency (EMA) guidelines [2]. 
Objectives 
To realize pediatric formulation according to the needs of different hospitals 
 To verify the quality [3-4] and also the stability [2] of the medicinal products under different environmental conditions 
 
The study of pediatric formulation is very important considering that the availability of preparations designed for children is limited. Furthermore 
should not be underestimated the extremely high incidence of counterfeit medicines in DC [5]. 
For pediatric use suppository and liquid preparations for oral use should be preferred; in particular liquid preparations allow a simple modulation 
of the amount in function of the weight of several children afferent to the hospital. 
 
The main goal of the stability study is that the preparations could therefore be  preserved in complete safety at homes even if these houses, as 
often happens in DC, are not equipped with air conditioners or refrigerators. 
Conclusion 
 About 30 galenic medicinal products for pediatric use have been studied and then formulated. 
 For all formulations quality and stability have been demonstrated in accordance with EMA guidelines. 
 The studied pediatric formulations are currently in use in the A.P.P.A.® laboratories of Haiti and Angola. 
Methodological  approach 
In agreement whit local medical doctors the drugs for the pediatric therapy are chosen and then formulated [6]: liquid oral formulations are preferred and appropriate excipients are 
selected. 
For each formulation a specific card (written in local language) has been prepared. The card shows the procedure of preparation and the characteristics of each component present in 
the formulation. 
Each preparation have been tested to check its quality and its stability under different environmental conditions in accordance with the EMA guidelines.  
Achieved Results 
The galenic medicines studied until now for pediatric use have been prepared in different pharmaceutical forms: 
Solutions: captopril, furosemide 
Suspension: amoxicillin, carbocysteine, chloramphenicol, erythromycin, magnesium and aluminum hydroxide, metronidazole, vitamin B complex 
Syrups: ascorbic acid, carbocysteine, ibuprofen, iron sulphate, paracetamol, potassium canrenoate, propranolol, quinine, ranitidine, salbutamol, vitamin B6 
Drops: nifedipine, quinine, ranitidine, salbutamol, vitamin B6 
Suppositories: paracetamol 
 
For each preparation specific tests were performed to verify the quality and also the stability under different environmental conditions, in accordance with the EMA guidelines . Up 
today, all formulations have proved to be stable in “Refrigerated” conditions (T=5±3 °C) and “Standard” conditions (T=40±2 °C, UR 60±5%) for 12 months, in “Accelerated” conditions 
(T=25±2 °C, UR 60±5%) for 3 months.  
TEST CONDITIONS 
STORAGE 
CONDITION T (°C) RH PERIOD COVERED BY DATA ANALYTICAL METHOD 
Standard 25±2 50±5% analysis at time zero (T0) and every 30 days (from TS-1 to TS-n) 
UV-VIS 
spectrophotometric assay 
Refrigerator 5±3 - analysis at time zero (T0) and every 30 days (from TS-1 to TS-n) 
UV-VIS 
spectrophotometric assay 
Accelerated 40±2 50±5% 
3 months, analysis at time zero (T0) 
and every 30 days  (from TA-1 
through TA-3) 
UV-VIS 
spectrophotometric assay 
“Pharmacien de la route” 
Operator of the A.P.P.A.® lab of Haiti Card for the preparation of the Propranolol syrup 
Considering the environmental conditions present in DC where the galenic products will be use 
and in order to investigate the stability of these medicinal products, A.P.P.A.® 
performed a survey of the stability of various galenic dosage forms using different environmental 
conditions in accordance with the EMA guidelines. We endeavoured to gather information on 
stability of galenics at extreme environmental conditions (high temperatures and relative 
humidity) that might prove useful in those Countries (e.g., African ones) where the tropical climate 
is a serious threat for the quality of drugs. Stability results of samples stored in “accelerated” 
(T=40±2°C, RH=50±5%) conditions supplied precious information on the expected stability of 
galenics in tropical Countries where extreme environmental conditions are often a limiting factor 
for correct storage of drugs.  
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